University of Western Australia Study finds nasal spray could aid battle against COVID
Nasodine Nasal Spray is based on povidone-iodine, the same active ingredient found in Betadine throat gargle, and has been in development for almost a decade as a treatment for the common cold. Laboratory experiments showed a 15-second exposure to the nasal spray reduced infectivity of SARS-CoV-2 by 99.97 per cent, while a 60-second exposure completely eliminated viral infectivity.
A subsequent pilot study of six COVID-19 patients, who were shedding the virus from the nose, looked at whether the laboratory results translated to people.
The trial showed that a single Nasodine dose (four sprays per nostril) reduced viral shedding in five of the six subjects (83 per cent) at five minutes after the dose, with an overall 79 per cent reduction in viral shedding at one hour after the dose.
Nasodine Nasal Spray is based on povidone-iodine, the same active ingredient found in Betadine throat gargle, and has been in development for almost a decade as a treatment for the common cold. Laboratory experiments showed a 15-second exposure to the nasal spray reduced infectivity of SARS-CoV-2 by 99.97 per cent, while a 60-second exposure completely eliminated viral infectivity.
The trial showed that a single Nasodine dose (four sprays per nostril) reduced viral shedding in five of the six subjects (83 per cent) at five minutes after the dose, with an overall 79 per cent reduction in viral shedding at one hour after the dose.https://www.uwa.edu.au/news/Article/2022/February/Study-find...